Danaher Profit, Revenue Rise, Upgrades Full-Year Outlook

By Adriano Marchese

Danaher reported higher second-quarter profit and revenue driven by a strong performance at its Life Sciences business, prompting the company to raise its outlook for the year.

The life sciences, biotechnology, and diagnostics company on Tuesday posted net income of $870 million, or $1.23 a share, compared with $555 million, or 77 cents a share, in the same quarter a year ago.

Adjusted earnings were $1.94 a share, topping expectations of $1.84 a share, according to a poll on FactSet.

Revenues rose 5.5% to $6.3 billion, ahead of projections of $6.11 billion.

Chief Executive Rainer Blair credits the quarter's performance in part to the company's Life Sciences segment, which he said had a strong quarter. "Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter," Blair said.

For the third quarter, Danaher expects adjusted core revenue to increase between 2% to 3%.

For full year, adjusted core revenue is projected to increase 3% to 4% with adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55. Analysts expect for the year $8.45 a share.

"Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate," Blair said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

July 21, 2026 06:37 ET (10:37 GMT)